Immunomodulators Market Size

Immunomodulators Market Size

The global immunomodulators market size was valued at around USD 217.7 billion in 2023 and is estimated to grow at 6.7% CAGR from 2024 to 2032. Immunomodulators are agents that modify or regulate one or more immune functions. These substances can either enhance the immune system's activity (immunostimulants) or suppress it (immunosuppressants), making them crucial for treating a wide range of conditions, including autoimmune diseases, cancers, and chronic infections.

The market is driven by the rising prevalence of autoimmune and inflammatory diseases, breakthroughs in biotechnological and pharmaceutical research, and heightened awareness of these therapies. Additionally, increased healthcare spending and a growing demand for effective treatments are fueling this growth. The surge in post-COVID complications has significantly broadened the immunomodulator market. A recent study highlighted that post-COVID-19 respiratory challenges have intensified the demand for immunotherapies, particularly due to restricted access to vaccines. These proven approaches aim to bolster the host's immunity against the virus, and this trend is expected to drive market growth in the coming years.
 

To gain a competitive edge, organizations are prioritizing the expansion of their customer base. In response, key players are actively pursuing strategic initiatives, including mergers, acquisitions, and partnerships with other industry leaders. For instance, in February 2021, Merck & Co., Inc. announced the acquisition of Pandion Therapeutics, Inc., a clinical-stage biotech firm focused on innovative therapeutics for autoimmune diseases. Leveraging its TALON technology, Pandion Therapeutics had developed a strong pipeline of candidates aimed at rebalancing immune responses to target a broad spectrum of autoimmune diseases. This acquisition helped Merck & Co., Inc. bolster its strategy of identifying and acquiring candidates with unique and potentially foundational traits.